Tumor-associated Macrophages in Breast Cancer

Overview

Journal J Mammary Gland Biol Neoplasia

Date 2002 Dec 5

PMID 12463738

Citations 169

Authors

Russell D Leek

Adrian L Harris

Affiliations

Soon will be listed here.

Abstract

Neoplastic cells form only one part of a complex network of cell types that make up a breast tumor. The normal cell types that make up the nonneoplastic components of tumors include fibroblasts, endothelium, and inflammatory cells, such as tumor associated macrophages (TAMs). TAMs have the potential to carry out both anti- and protumor activities In their antitumor role TAMs can present tumor antigens to cytotoxic T-cells and are capable of being directly cytotoxic to neoplastic cells. Conversely, TAMs are also able to promote tumor growth directly by secreting breast tumor mitogens, such as epidermal growth factor, and indirectly by stimulating tumor angiogenesis and metastasis. Recent studies have indicated that in breast cancers the protumor role of TAMs is dominant, and that TAMs may be executing a "wound healing" type of process in response to stimuli found in the tumor microenvironment, such as hypoxia. As such, TAMs may provide opportunities for future therapeutic interventions.

Citing Articles

Three-Dimensional Models: Biomimetic Tools That Recapitulate Breast Tissue Architecture and Microenvironment to Study Ductal Carcinoma In Situ Transition to Invasive Ductal Breast Cancer.

Shah S, Osuala K, Brock E, Ji K, Sloane B, Mattingly R Cells. 2025; 14(3).

PMID: 39937011 PMC: 11817749. DOI: 10.3390/cells14030220.

The Microenvironment in DCIS and Its Role in Disease Progression.

Roozitalab M, Prekete N, Allen M, Grose R, Jones J Adv Exp Med Biol. 2025; 1464():211-235.

PMID: 39821028 DOI: 10.1007/978-3-031-70875-6_12.

The role of macrophage migratory behavior in development, homeostasis and tumor invasion.

Murrey M, Ng I, Pixley F Front Immunol. 2024; 15:1480084.

PMID: 39588367 PMC: 11586339. DOI: 10.3389/fimmu.2024.1480084.

SFRP1 decreases WNT-Mediated M2 macrophage marker expression in breast tissue.

Gregory K, Mason H, Casaubon J, Schneider S Cancer Immunol Immunother. 2024; 73(5):86.

PMID: 38554160 PMC: 10981600. DOI: 10.1007/s00262-024-03638-0.

Defining and targeting macrophage heterogeneity in the mammary gland and breast cancer.

Elfstrum A, Bapat A, Schwertfeger K Cancer Med. 2024; 13(3):e7053.

PMID: 38426622 PMC: 10905685. DOI: 10.1002/cam4.7053.

References

Kacinski B . CSF-1 and its receptor in ovarian, endometrial and breast cancer. Ann Med. 1995; 27(1):79-85. DOI: 10.3109/07853899509031941. View

Nilsson T, Woods A, Rofe A . In vivo studies of macrophages and intercellular adhesion molecule-1 following lipopolysaccharide treatment in tumour-bearing rats. Immunol Cell Biol. 1996; 74(5):408-12. DOI: 10.1038/icb.1996.70. View

Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S . Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res. 2001; 7(5):1459-65. View

Brown P . Matrix metalloproteinase inhibitors. Breast Cancer Res Treat. 1999; 52(1-3):125-36. DOI: 10.1023/a:1006119319695. View

Walker R, Dearing S, Gallacher B . Relationship of transforming growth factor beta 1 to extracellular matrix and stromal infiltrates in invasive breast carcinoma. Br J Cancer. 1994; 69(6):1160-5. PMC: 1969439. DOI: 10.1038/bjc.1994.228. View

Ross J, Fletcher J . HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol. 1999; 112(1 Suppl 1):S53-67. View

Denoyelle C, Vasse M, Korner M, Mishal Z, Ganne F, Vannier J . Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis. 2001; 22(8):1139-48. DOI: 10.1093/carcin/22.8.1139. View

Bertrand P, Girard N, Duval C, dAnjou J, Chauzy C, Menard J . Increased hyaluronidase levels in breast tumor metastases. Int J Cancer. 1997; 73(3):327-31. DOI: 10.1002/(sici)1097-0215(19971104)73:3<327::aid-ijc4>3.0.co;2-1. View

Baumgartner G, Sakr L, Ulsperger E, Wogritsch C . The impact of extracellular matrix on the chemoresistance of solid tumors--experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy. Cancer Lett. 1998; 131(1):85-99. View

10.

Thomsen L, Miles D . Role of nitric oxide in tumour progression: lessons from human tumours. Cancer Metastasis Rev. 1998; 17(1):107-18. DOI: 10.1023/a:1005912906436. View

11.

Crowther M, Brown N, Bishop E, Lewis C . Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors. J Leukoc Biol. 2001; 70(4):478-90. View

12.

Harmey J, Dimitriadis E, Kay E, Redmond H, Bouchier-Hayes D . Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1. Ann Surg Oncol. 1998; 5(3):271-8. DOI: 10.1007/BF02303785. View

13.

Miles D, Happerfield L, Naylor M, Bobrow L, Rubens R, Balkwill F . Expression of tumour necrosis factor (TNF alpha) and its receptors in benign and malignant breast tissue. Int J Cancer. 1994; 56(6):777-82. DOI: 10.1002/ijc.2910560603. View

14.

Hildenbrand R, Dilger I, Horlin A, STUTTE H . Urokinase and macrophages in tumour angiogenesis. Br J Cancer. 1995; 72(4):818-23. PMC: 2034060. DOI: 10.1038/bjc.1995.419. View

15.

Nath D, Hartnell A, Happerfield L, Miles D, Burchell J, Taylor-Papadimitriou J . Macrophage-tumour cell interactions: identification of MUC1 on breast cancer cells as a potential counter-receptor for the macrophage-restricted receptor, sialoadhesin. Immunology. 1999; 98(2):213-9. PMC: 2326916. DOI: 10.1046/j.1365-2567.1999.00827.x. View

16.

Relf M, Lejeune S, Scott P, Fox S, Smith K, Leek R . Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human.... Cancer Res. 1997; 57(5):963-9. View

17.

Liu D, Buluwela L, Ali S, Thomson S, Gomm J, Coombes R . Retroviral infection of the FGF2 gene into MCF-7 cells induces branching morphogenesis, retards cell growth and suppresses tumorigenicity in nude mice. Eur J Cancer. 2001; 37(2):268-80. DOI: 10.1016/s0959-8049(00)00392-0. View

18.

Kaklamanis L, Leek R, Koukourakis M, Gatter K, Harris A . Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. Cancer Res. 1995; 55(22):5191-4. View

19.

Clauss M, Gerlach M, Gerlach H, Brett J, Wang F, Familletti P . Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med. 1990; 172(6):1535-45. PMC: 2188755. DOI: 10.1084/jem.172.6.1535. View

20.

Tressler R, Pitot P, Stratton J, Forrest L, Zhuo S, Drummond R . Urokinase receptor antagonists: discovery and application to in vivo models of tumor growth. APMIS. 1999; 107(1):168-73. DOI: 10.1111/j.1699-0463.1999.tb01540.x. View